Related Experiment Video
Updated: Jul 21, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Intravenous Immunoglobulin in Kawasaki Disease-Evolution and Pathogenic Mechanisms
Pallavi L Nadig1, Vibhu Joshi1, Rakesh Kumar Pilania1
1Pediatric Allergy Immunology Unit, Department of Pediatrics, Postgraduate Institute of Medical Education & Research, Chandigarh 160012, India.
Insights
Intravenous immunoglobulin (IVIg) effectively prevents coronary artery aneurysms in Kawasaki disease (KD). This review explores IVIg
Area of Science:
- Pediatric rheumatology
- Immunology
- Vascular biology
Background:
- Kawasaki disease (KD) is a childhood vasculitis impacting medium vessels, particularly coronary arteries.
- Coronary artery aneurysms (CAAs) are a major complication, occurring in 25-30% of untreated cases.
- Intravenous immunoglobulin (IVIg) reduces CAA risk to under 5%, but its immunomodulatory mechanisms are unclear.
Purpose of the Study:
- To review the potential mechanisms of IVIg's immunomodulatory actions in Kawasaki disease.
- To summarize evidence on IVIg infusion protocols and dosages for KD treatment.
Main Methods:
- Review of existing literature on IVIg's effects in Kawasaki disease.
- Analysis of studies investigating innate and adaptive immune system modulation by IVIg.
- Examination of data on treatment protocols and dosages.
Main Results:
- IVIg appears to modulate innate immunity via toll-like receptor pathways, autophagy, apoptosis, neutrophil extracellular traps, and dendritic cells.
- IVIg also influences adaptive immunity by affecting T-cell differentiation, cytokine release, and regulatory T-cell function.
- Evidence regarding various IVIg infusion protocols and dosages in KD treatment is summarized.
Conclusions:
- IVIg exerts immunomodulatory effects on both innate and adaptive immune systems in Kawasaki disease.
- Understanding these mechanisms can optimize KD treatment strategies and improve patient outcomes.
- Further research is needed to fully elucidate IVIg's complex actions in KD.
Abstract:
Kawasaki disease (KD) is an acute vasculitis of childhood that affects the medium vessels with a special predilection to the involvement of coronary arteries. The major morbidity of this disease is due to coronary artery aneurysm, which occurs in about 25-30% of untreated cases. For decades now, intravenous immunoglobulin (IVIg) has consistently been shown to reduce the risk of CAAs to less than 5%. However, the mechanism of immunomodulation remains unclear. Several studies on the role of IVIg in the modulation of toll-like receptor pathways, autophagy, and apoptosis of the mononuclear phagocytic system, neutrophil extracellular trap, and dendritic cell modulation suggest a modulatory effect on the innate immune system. Similarly, certain studies have shown its effect on T-cell differentiation, cytokine release, and regulatory T-cell function. In this review, we discuss the potential mechanisms underlying the immunomodulatory actions of IVIg in patients with Kawasaki disease. Furthermore, we provide a summary of the evidence regarding various infusion protocols and dosages utilized in the treatment of KD patients.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction
Myocarditis III: Medical Management
Myocarditis I: Introduction
Nephrotic Syndrome I : Introduction

